Inflammatix lands $12.1M in new BARDA deal

By LabPulse.com staff writers

November 19, 2021 -- Molecular diagnostics firm Inflammatix has received a $12.1 million contract extension from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a test that characterizes infections.

The company's third tranche of funding from BARDA is part of a contract worth up to $72 million if all options are exercised. Inflammatix said it would use the funds for ongoing development and clinical studies of its ViraBac EZ acute infection test, which determines whether a suspected infection is bacterial or viral based on gene expression patterns in the immune system.

In addition, the funding will also support development of the machine learning-based, point-of-care system on which ViraBac EZ and all Inflammatix tests are run, according to the vendor. BARDA is part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.

Inflammatix wins $1.7M NIH grant
Inflammatix has won a $1.7 million grant from the U.S. National Institutes of Health (NIH) that it plans to use to develop a rapid diagnostic test...
Inflammatix secures $102M in financing
Molecular diagnostics firm Inflammatix has secured $102 million in financing that it plans to use to commercialize its novel immune response diagnostics...
Inflammatix secures $7.4M in BARDA funding
Molecular diagnostics firm Inflammatix has secured an additional $7.4 million in funding from the Biomedical Advanced Research and Development Authority...
Inflammatix gets $32M infusion for HostDx rapid POC tests
California startup Inflammatix has raised $32 million in series C financing, which it plans to use to move its HostDx rapid point-of-care (POC) tests...
Inflammatix scores BARDA contract for infection tests
Startup Inflammatix is set to get $6 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and up to $72 million...

Copyright © 2021 LabPulse.com

Last Updated ls 11/19/2021 12:16:12 PM